Analyst consensus rating
Spruce Biosciences Analyst Rating: Strong Buy
Direct answer
Spruce Biosciences's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $147.89.
Forecast evidence checked November 12, 2026.
Get free Spruce Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $46.20
- Average price target
- $147.89
- High price target
- $230.00
- Low price target
- $104.00
- Low target gap
- +125.1%
- Target upside
- +220.1%
- High target gap
- +397.8%
- Target range width
- 272.7%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Spruce Biosciences?
Spruce Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $147.89.
How far are Spruce Biosciences's low and high targets from the recorded price?
The low target implies +125.1%, while the high target implies +397.8%.
How many analysts are included in Spruce Biosciences's consensus?
The verified consensus includes 9 analysts.
How is Spruce Biosciences's target upside or downside calculated?
The average target of $147.89 is divided by the recorded price of $46.20, then one is subtracted to produce +220.1%. This does not guarantee a future return.
When was Spruce Biosciences's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.